title: Exploration of liquid and supercritical fluid chromatographic chiral separation and purification of Nutlin-3--a small molecule antagonist of MDM2.
abstract: Inhibition of the MDM2-p53 interaction can stabilize the p53 protein and offer a novel strategy for cancer therapy. The imidazoline compound (Nutlin-3) is a promising small molecule antagonist of the MDM2-p53 interaction. This compound was synthesized as a racemic mixture, and one enantiomer is 100-200-fold more active than the other enantiomer. In this study, various enantiomeric separation approaches were explored to resolve the Nutlin-3 enantiomers using chiral supercritical fluid chromatography (SFC) as well as chiral liquid chromatography (LC) under normal phase mode, reversed phase mode and polar organic phase mode. The chiral SFC method based on Chiralcel OD column showed superior separation in terms of selectivity and efficiency. Optimization of the chiral separation method enabled high throughput preparative scale purification. Ultimately, 5 g of racemic mixture were purified on Prep-SFC in 75 min with the recovery rate above 92%.
authors: Discovery Chemistry, Hoffmann-La Roche Inc., Nutley, NJ 07110, USA. zhenyu.wang@roche.com
authors: Zhenyu
authors: Z
authors: Wang
authors: Malgorzata
authors: M
authors: Jonca
authors: Ted
authors: T
authors: Lambros
authors: Stephen
authors: S
authors: Ferguson
authors: Robert
authors: R
authors: Goodnow
mesh_terms: D002853:Chromatography, Liquid; D025924:Chromatography, Supercritical Fluid / Q000379:methods*; D007093:Imidazoles / Q000138:chemical synthesis / Q000737:chemistry / Q000302:isolation & purification*; D015394:Molecular Structure; D010879:Piperazines / Q000138:chemical synthesis / Q000737:chemistry / Q000302:isolation & purification*; D051736:Proto-Oncogene Proteins c-mdm2 / Q000037:antagonists & inhibitors*; D013237:Stereoisomerism; D013678:Technology, Pharmaceutical / Q000379:methods*; D013997:Time Factors
chemical_list: D007093:Imidazoles; D010879:Piperazines; C482205:nutlin 3; D051736:Proto-Oncogene Proteins c-mdm2